Loading
A phase 2 trial of Intismeran autogene, Pembrolizumab, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Merck Sharp & Dohme LLC, now recruiting.
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) is a phase 2 interventional study registered as NCT07221474 by Merck Sharp & Dohme LLC, with 180 participants planned, started 2025-12-12 and due to reach its primary completion in 2029-07-02. Interventions recorded: Intismeran Autogene, Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel. Conditions listed: Squamous Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Merck & Co. (MSD), Small-cell lung cancer.
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Merck & Co. (MSD), Pembrolizumab.
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Merck & Co. (MSD), Carboplatin.
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Merck & Co. (MSD), Small-cell lung cancer.
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Merck & Co. (MSD), Pembrolizumab.
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Merck & Co. (MSD), Pembrolizumab.
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Merck & Co. (MSD).
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Pembrolizumab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/